Filing Date Form TypeDescription   
   
Data pager
 Page 1 of 6, items 1 to 13 of 77.
2021-02-043Initial statement of beneficial ownership of securitiesAcc-no: 0001415889-21-000531 Size: 3 KB
2021-01-113Initial statement of beneficial ownership of securitiesAcc-no: 0001415889-21-000278 Size: 12 KB
2020-06-104Statement of changes in beneficial ownership of securitiesAcc-no: 0001415889-20-001541 Size: 4 KB
2020-06-104Statement of changes in beneficial ownership of securitiesAcc-no: 0001415889-20-001540 Size: 4 KB
2020-01-173Initial statement of beneficial ownership of securitiesAcc-no: 0001415889-20-000114 Size: 13 KB
2020-01-163Initial statement of beneficial ownership of securitiesAcc-no: 0001415889-20-000109 Size: 13 KB
2020-01-153Initial statement of beneficial ownership of securitiesAcc-no: 0001415889-20-000105 Size: 13 KB
2019-06-044Statement of changes in beneficial ownership of securitiesAcc-no: 0001415889-19-000646 Size: 4 KB
2019-06-044Statement of changes in beneficial ownership of securitiesAcc-no: 0001415889-19-000645 Size: 4 KB
2019-03-264Statement of changes in beneficial ownership of securitiesAcc-no: 0001415889-19-000390 Size: 4 KB
2019-03-264Statement of changes in beneficial ownership of securitiesAcc-no: 0001415889-19-000388 Size: 4 KB
2019-03-224Statement of changes in beneficial ownership of securitiesAcc-no: 0001415889-19-000377 Size: 8 KB
2019-02-085Annual statement of changes in beneficial ownership of securitiesAcc-no: 0001415889-19-000143 Size: 8 KB


Sensus Healthcare Granted U.S. Patent for Three-Dimensional Beam Forming X-Ray Source
02/23/2021 1:00 PM

Patent covers beam splitting and sculpting capabilities of radiation to treat all types of solid tumors with Sculptura™ and potentially other devices
Patent covers beam splitting and sculpting capabilities of radiation to treat all types of solid tumors with Sculptura™ and potentially other devices

Sensus Healthcare to Host Fourth Quarter 2020 Financial Results and Business Update Conference Call on February 25, 2021
02/18/2021 1:00 PM

BOCA RATON, Fla, Feb. 18, 2021 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces that management will hold a conference call on Thursday, February 25, 2021 at 4:30 p.m. Eastern time to discuss the financial results for the fourth quarter of 2020. In addition, management will provide a business update and a discussion on recent and upcoming milestones.


Holy Name Medical Center in Teaneck, New Jersey Acquires Sensus Healthcare’s Low-dose Radiation Therapy System to Treat Pneumonia in COVID-19 Patients
01/06/2021 2:32 PM

BOCA RATON, Fla., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, today announced Holy Name Medical Center in Teaneck, New Jersey has acquired a Sensus low-dose radiation therapy system for the treatment of pneumonia in COVID-19 patients.


Sensus Healthcare Engages Ekpac Healthcare Ltd. as New Exclusive Distributor in China for SRT-100™ Systems
12/15/2020 1:00 PM

Agreement is for the treatment of non-melanoma skin cancer and keloids, covers China and Hong Kong and is effective January 1, 2021
Agreement is for the treatment of non-melanoma skin cancer and keloids, covers China and Hong Kong and is effective January 1, 2021

Sensus Healthcare Announces CMS Sets Rates Higher for SRT Reimbursement
12/08/2020 1:00 PM

 BOCA RATON, Fla, Dec. 08, 2020 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces that the Centers for Medicare & Medicaid Services (CMS) has issued a new, final reimbursement amount for CPT® code 77401 of approximately $41 per treatment.  CPT code 77401 covers the delivery of Superficial Radiation Therapy (SRT) and this new amount represents a 66% increase from current levels.  This is the first meaningful revaluation of CPT code 77401 since 2002.


Sensus Healthcare Announces Study Showing Single Low Dose of Superficial Radiation Therapy Prevents Keloid Recurrence Following Surgical Excision
12/01/2020 1:00 PM

Prospective study published in Journal of the American Academy of Dermatology


Sensus Healthcare Reports Third Quarter 2020 Financial Results
11/05/2020 9:02 PM

Conference call begins at 4:30 p.m. Eastern time today
Conference call begins at 4:30 p.m. Eastern time today

Sensus Healthcare Appoints Megan Cornish to its Board of Directors
11/05/2020 1:00 PM


Sensus Healthcare to Host Third Quarter 2020 Financial Results and Business Update Conference Call on November 5, 2020
10/29/2020 3:18 PM

BOCA RATON, Fla. , Oct. 29, 2020 (GLOBE NEWSWIRE) --  Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces that management will hold a conference call on Thursday, November 5, 2020 at 4:30 p.m. Eastern time to discuss the financial results for the third quarter of 2020. In addition, management will provide a business update and a discussion on recent and upcoming milestones.


Sensus Healthcare Announces Publication of Study Showing Use of Superficial Radiation Therapy Post-Keloidectomy Prevents Keloid Recurrence
10/22/2020 12:00 PM

BOCA RATON, Fla., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces the publication of a retrospective study showing keloidectomy followed by superficial radiation therapy (SRT) had an approximate 10% recurrence rate, compared with an expected recurrence rate of more than 80% following surgical excision alone.  The study was published in the Journal of Clinical and Aesthetic Dermatology and can be found here.  Authors were:


Sensus Healthcare Reports Second Quarter 2020 Financial Results
08/06/2020 8:02 PM

Conference call begins at 4:30 p.m. Eastern time today
Conference call begins at 4:30 p.m. Eastern time today

American Society of Radiologic Technologists Approves Sensus Healthcare’s SRT Systems for Continuing Education Units
08/05/2020 12:30 PM

Beginning September 1, Category A credits will be available for in-person trainings on the SRT-100™, SRT-100+™ and SRT-100 Vision™ systems


Sensus Healthcare Acquires Two Mobile Aesthetic Laser Companies in Florida
08/04/2020 12:30 PM


Sensus Healthcare to Host Second Quarter 2020 Financial Results and Business Update Conference Call on August 6, 2020
07/30/2020 12:30 PM

BOCA RATON, Fla. , July 30, 2020 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces that management will hold a conference call on Thursday, August 6, 2020 at 4:30 p.m. Eastern time to discuss the financial results for the second quarter of 2020. In addition, management will provide a business update and a discussion on recent and upcoming milestones.


Sensus Healthcare Names Hoi-Bun “Benson” Suen Vice President of International Sales, Ships SRT-100™ to China
07/28/2020 12:30 PM

BOCA RATON, Fla. , July 28, 2020 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces the appointment of Hoi-Bun “Benson” Suen as Vice President of International Sales.  Mr. Suen will focus on sales of the Company’s Superficial Radiation Therapy (SRT) products across Southeast Asia and will report directly to Joe Sardano, chief executive officer.  The Company is also announcing the resumption of shipments to China with the sale of an SRT-100™ system, a direct result of Mr. Suen’s efforts.


Evidence-Based Guidelines Issued by ASTRO Support Sensus Healthcare’s SRT Technology as the First-Line Alternative to Surgery for Treating Non-Melanoma Skin Cancer
07/14/2020 12:00 PM

Influential professional organization recommends radiotherapy as the primary non-surgical alternative for patients with basal cell or cutaneous squamous cell carcinomas


Sensus Healthcare to Present at COVID-19 Webinar Hosted by Maxim Group on July 16th
07/13/2020 8:02 PM

BOCA RATON, Fla., July 13, 2020 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announced today that Joe Sardano, Sensus’ chief executive officer has been invited to present at the Re-Engaging Medical Practices in an Era of COVID-19  webinar, presented by Maxim Group and M-Vest on Thursday, July 16, 2020.


Sensus Healthcare’s CEO to Participate in Dermatology Practice Panel Discussion as Part of the Fall Clinical Virtual Grand Rounds Weekly Series
06/30/2020 12:30 PM

BOCA RATON, Fla. , June 30, 2020 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces that Joe Sardano, the company’s chief executive officer, will participate in a panel discussion today at the Fall Clinical Virtual Grand Rounds Weekly Continuing Education Series. The program, titled “Directions in Dermatology and Their Impact on You: Patients, Practice and Pharma,” is part of the recent online series titled “Evolving Concepts in Dermatology; Dermatology Industry LeadersThe Path Forward.


Sensus Healthcare Announces CME Presentation by Dr. Jeffrey S. Fromowitz Today at the Fall Clinical Virtual Grand Rounds Series
06/24/2020 12:30 PM


Sensus Healthcare and David Goldberg, M.D., J.D. to Host a Virtual Program on Dermatology Medical and Legal Issues in the Era of COVID-19
06/03/2020 12:30 PM

June 18 Event is the Third in a Series of Topical Discussions